Masyar Gardizi
Kerpener Str. 62
Koeln, NW 50937, Germany
Koeln, NW 50937, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Journal: Cancer medicine
Published: December 17, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 13, 2018
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 24, 2015
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 23, 2015
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 11, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Journal: Oncotarget
Published: October 22, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Journal: Nature medicine
Published: January 27, 2014
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
Journal: Cancer discovery
Published: December 05, 2013
Activated RET and ROS: two new driver mutations in lung adenocarcinoma.
Journal: Translational lung cancer research
Published: February 10, 2013
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 29, 2013
A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma.
Journal: Archives of dermatological research
Published: November 09, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026